Cell sensitivity assays: the ATP-based tumor chemosensitivity assay

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• The ATP-based tumor chemosensitivity assay (ATP-TCA) is a validated method for evaluating anticancer drug efficacy.
• It is adaptable for use with both cell lines and primary tumor cells, supporting diverse research applications.

Purpose of the Study:

• To detail the standardized ATP-TCA method for assessing tumor cell chemosensitivity.
• To highlight its utility in drug development, chemoresistance research, and clinical decision support.

Main Methods:

• Cell extraction from various sources including cell cultures, effusions, and biopsies.
• Enzymatic digestion for solid tumor tissues, followed by a 6-day incubation in serum-free medium on polypropylene plates.
• Cellular ATP measurement via luciferin-luciferase assay to determine drug-induced inhibition.

Main Results:

• The assay quantifies drug effects as percentage inhibition across tested concentrations.
• Results can be analyzed with software to evaluate synergistic interactions between anticancer agents.
• The method effectively distinguishes neoplastic from non-neoplastic cells.

Conclusions:

• The ATP-TCA is a robust and versatile tool for preclinical and clinical cancer research.
• It offers valuable insights into drug response, resistance mechanisms, and combination therapy strategies.
• Standardized protocols ensure reliable data for drug development and patient treatment guidance.